A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- The severity of COVID-19
研究概览
简要总结
This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available.
排除标准
- •Patients who could not provide detailed information about COVID-19 infection.
结局指标
主要结局
The severity of COVID-19
时间窗: 2 months
The severity of COVID-19 infection in maligant lymphoma patients evaluated by investigators
Hospital admission rate of COVID-19 infection
时间窗: 2 months
The percentage of malignant lymphoma patients who were admitted into hospital
次要结局
未报告次要终点
研究者
Li Zhiming
Prof.
Sun Yat-sen University